Skip to main content
Sigyn Therapeutics Inc. logo

Sigyn Therapeutics Inc. — Investor Relations & Filings

Ticker · SIGY ISIN · US82674U2050 Manufacturing
Open in API
Filings indexed 6 across all filing types
Latest filing 2026-04-02 Regulatory Filings
Country US United States of America
Listing — SIGY

About Sigyn Therapeutics Inc.

https://www.sigyntherapeutics.com/

Sigyn Therapeutics Inc. is a development-stage medical technology company focused on creating novel blood purification therapies to address life-threatening conditions. The company's core platform, Sigyn Therapy™, is a dialysis-like technology designed to remove a broad spectrum of pathogenic and inflammatory targets from the bloodstream. It is being developed to treat conditions with significant unmet medical needs, including pathogen-associated inflammatory disorders precipitated by cytokine storm syndrome, cardiovascular disease, and cancer. Key therapeutic candidates include Sigyn CardioDialysis™, which aims to reduce inflammatory molecules and cholesterol-transporting lipoproteins, and ChemoPrep™, a therapy for cancer.

Recent filings

Filing Released Lang Actions
Sigyn Therapeutics Launches Initiative to Evaluate Emerging Medical Technologies in Former NFL Players at Risk of CTE
Regulatory Filings Classification · 85% confidence The document is a corporate press release describing Sigyn Therapeutics launching a medical initiative. It contains forward-looking statements and company background, but no financial results, no voting outcomes, no management changes, no regulatory form filings or data attachments. It is a general corporate announcement/press release, which falls under the Miscellaneous Regulatory Filings fallback category. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2026-04-02 English
CardioDialysisTM, a Next-Generation Technology to Reduce Major Adverse Cardiovascular Events
Regulatory Filings Classification · 78% confidence The document is a corporate press release announcing product development (CardioDialysis™) and includes forward-looking statements. It does not report financial results, management changes, capital markets activity, or regulatory/legal actions. It is a general corporate news announcement that does not fit any narrow category, making it a fallback Regulatory Filing.
2026-03-27 English
Scientific American Highlights Scientific Discovery That Supports the Potential Use of CardioDialysis(TM) to Treat Neuroinflammatory Diseases
Regulatory Filings Classification · 75% confidence The document is a corporate press release published via EQS News detailing a scientific discovery and strategic positioning of a technology (CardioDialysis) by Sigyn Therapeutics. It contains no financial results, governance changes, proxy materials, or formal periodic filings; instead, it is a general corporate announcement. Therefore it falls under the fallback category for miscellaneous regulatory announcements.
2026-03-24 English
Sigyn Therapeutics Issues Shareholder Update Regarding Potential Merger and Asset Sale Initiatives
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sigyn Therapeutics, Inc. titled 'Sigyn Therapeutics Issues Shareholder Update Regarding Potential Merger and Asset Sale Initiatives'. It discusses strategic business initiatives, including potential mergers and asset sales, and provides a narrative update from the CEO. While it mentions M&A activity, it is a corporate news release rather than a formal M&A filing (like a definitive agreement or proxy statement). It does not fit the criteria for a formal report (10-K, IR) or a specific regulatory filing, and is best classified as a general corporate news announcement under the Regulatory Filings (RNS) category.
2026-03-13 English
Sigyn Therapeutics Issues Shareholder Update Highlighting the Advancement of CardioDialysis(TM) and New Corporate Initiatives
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sigyn Therapeutics, Inc. titled 'Sigyn Therapeutics Issues Shareholder Update Highlighting the Advancement of CardioDialysis(TM) and New Corporate Initiatives'. It provides strategic updates on clinical pathways, potential Nasdaq merger opportunities, and financing strategies. While it contains significant corporate information, it is structured as a news announcement disseminated via a wire service (EQS News). It does not meet the criteria for a formal financial report (like a 10-K or IR) or a specific regulatory filing, but rather serves as a general corporate update/announcement. Therefore, it is best classified as a Regulatory Filing (RNS) under the provided definitions.
2026-01-15 English
The Emergence of Blood Purification Devices to Treat Cardiovascular Disease
Regulatory Filings Classification · 95% confidence The document is a corporate press release issued by Sigyn Therapeutics, Inc. regarding a note from their CEO about a medical device. It follows the standard format of a corporate news announcement disseminated via a wire service (EQS News). It does not constitute a formal regulatory filing like a 10-K or 10-Q, nor is it a transcript or a specific governance report. As it is a general corporate news release, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate announcements.
2026-01-06 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.